Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05018286 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
A Phase 3 study of Short Bowel Syndrome, sponsored by VectivBio.
- Active
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
- 20
- Study locations
NCT05018286: Active Phase 3 study of Short Bowel Syndrome, sponsored by VectivBio.
NCT05018286 is a Phase 3 study of Short Bowel Syndrome that is active but no longer recruiting, run by VectivBio. The registered enrollment target is 158 participants, below the 176-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05018286, a Phase 3 study of Short Bowel Syndrome, is active but no longer recruiting, sponsored by VectivBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
Primary Outcome
System organ class, frequency and severity
Conditions Studied
Interventions
- DRUG Apraglutide
Study Locations (20)
Other
- University Hospital Fundacion Favaloro - Buenos Aires
- University Hospital Brussels - Brussels
- UZ Leuven - Leuven
- University Hospital Brno - Brno
- University Hospital Hradec Kralove - Hradec Králové
- Hospital Novy Jicin - Nový Jičín
- University Hospital Plzen - Pilsen
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic Foundation - Cleveland
California
- Ronald Reagan UCLA Medical Center - Los Angeles
Florida
- Gastroenterology Group of Naples - Naples
Illinois
- Northwestern University - Chicago - Chicago
Michigan
- Henry Ford Health System - Detroit
Minnesota
- Mayo Clinic - Rochester - Rochester
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2027-10-30 |
| Phase | Phase 3 |
What the registry record for NCT05018286 still lists
NCT05018286 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, below the 176-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Apraglutide is the first listed.
NCT05018286 names 20 study sites across 13 states, led by Other, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT05018286 about?
NCT05018286 is a clinical study titled "Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.". The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
What is the current status of trial NCT05018286?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2021-07-13. Estimated completion is 2027-10-30.
What conditions does trial NCT05018286 study?
This clinical trial studies the following conditions: Short Bowel Syndrome.
What interventions are being tested in trial NCT05018286?
The interventions under investigation include: Apraglutide (DRUG).
Who is sponsoring clinical trial NCT05018286?
This trial is sponsored by VectivBio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05018286 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05018286's enrollment target sits among peer trials
158 3rd of 17 higher than 15 of 17 other Short Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Short Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RECRUITING · Phase 3
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
ACTIVE NOT RECRUITING · Phase 3
-
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
COMPLETED · Phase 3
-
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome
COMPLETED · Phase 3
-
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI